Fig. 5From: Payload diversification: a key step in the development of antibody–drug conjugatesSchematic representation of the ADC payload’s target landscape beyond microtubules and DNA-intercalating agents. Notations: FDA-approved ADCs, ADCs in clinical trialsBack to article page